冲刺连续28天净流入！资金持续配置中药ETF

Group 1 - The core viewpoint of the news highlights the mixed performance of the Chinese medicine sector, with specific stocks like Zhenbao Island and Yiling Pharmaceutical showing gains, while Zhaoli Pharmaceutical experienced a decline [1] - The Ministry of Industry and Information Technology is conducting a comprehensive survey of the Chinese medicine industry chain, emphasizing the need for high-standard raw material production bases and a quality traceability system to promote the standardized and ecological development of Chinese medicinal materials [1] - The report from Xinda Securities indicates a marginal improvement trend in the pharmaceutical industry, suggesting a potential market shift towards high-growth sectors supported by performance, with a focus on Q3 earnings, CXO, life sciences upstream, medical device recovery, and innovative drugs [1] Group 2 - The Chinese Medicine ETF closely tracks the CSI Chinese Medicine Index, which includes listed companies involved in the production and sales of Chinese medicine, reflecting the overall performance of the Chinese medicine concept stocks [2] - As of September 30, 2025, the top ten weighted stocks in the CSI Chinese Medicine Index accounted for 55.08% of the index, with notable companies including Yunnan Baiyao, Pian Zai Huang, and Tong Ren Tang [2]